The newly approved linvoseltamab (Lynozyfic; Regeneron) has a manageable safety profile, along with a patient-friendly dosing schedule that includes intravenous administration, step-up dosing, and ...

Mismatches in an immune cell surface receptor could contribute to higher transplant rejection rates, a new study finds.